Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HOPE

Financiado

Cerrado

Host Protective Engineering of Cancer Immunity by Targeting the Intracellular Im...

Host Protective Engineering of Cancer Immunity by Targeting the Intracellular Immune Checkpoint NR2F6 "Because of its biological complexity, cancer is still poorly understood. Chronic inflammation has been shown, both experimentally and epidemiologically, to be a predisposition to, and also an inseparable aspect of clinically prev... ver más

30/09/2024

MUI

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

MEDIZINISCHE UNIVERSITAT INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-09-30

ERC-2017-ADG: ERC Advanced Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

MUI

2.48M€ | Lider

INDUSTRIA JABONERA LINA

1.04M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DSMT16 Deciphering causes and consequences of inflammation in subty... 159K€ Cerrado

ReverT Reversing T cell dysfunction in cancer by multimodal genetic... 2M€ Cerrado

IISN-DC Understanding the functional role of Immune-related Intercel... 2M€ Cerrado

IMMUNOMARK Omics integration for precision cancer immunotherapy 170K€ Cerrado

EXPAND IT EXPANDing Immune Cells and their Tumor Antigens during check... 3M€ Cerrado

ImmunoFit Harnessing tumor metabolism to overcome immunosupression 2M€ Cerrado

Duración del proyecto: 74 meses Fecha Inicio: 2018-07-18
Fecha Fin: 2024-09-30

Líder del proyecto

MEDIZINISCHE UNIVERSITAT INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Because of its biological complexity, cancer is still poorly understood. Chronic inflammation has been shown, both experimentally and epidemiologically, to be a predisposition to, and also an inseparable aspect of clinically prevalent cancer entities. Therefore, a detailed understanding of both tumour and immune cell functions in cancer progression is a prerequisite for more successful therapeutic startegies. My team was the first to reveal the lymphocyte-intrinsic PKC/NR2F6 axis as an essential signalling node at the crossroads between inflammation and cancer. It is the mission of this project to identify molecular signatures that influence the risk of developing tumours employing established research tools and state-of-the-art genetic, biochemical, proteomic and transcriptomic as well as large scale CRISPR/Cas9 perturbation screening-based functional genomic technologies. Defining this as yet poorly elucidated effector pathway with its profoundly relevant role would enable development of preventive and immune-therapeutic strategies against NSCLC lung cancer and potentially also against other entities. Our three-pronged approach to achieve this goal is to: (i) delineate biological and clinical properties of the immunological PKC/NR2F6 network, (ii) validate NR2F6 as an immune-oncology combination target needed to overcome limitations to ""first generation anti-PD-1 checkpoint inhibitors"" rendering T cells capable of rejecting tumours and their metastases at distal organs and (iii) exploit human combinatorial T cell therapy concepts for prevention of immune-related adverse events as well as of tumour recurrence by reducing opportunities for the tumour to develop resistance in the clinic. Insight into the functions of NR2F6 pathway and involved mechanisms is a prerequisite for understanding how the microenvironment at the tumour site either supports tumour growth and spread or prevents tumour initiation and progression, the latter by host-protective cancer immunity."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores